| Officer | In this role | Source |
|---|---|---|
|
Peter Luo
Also a director
Co-Founder, Chief Executive Officer, President of R&D, and Chairman of the Board
|
Not stated | |
|
Man Kin (Raymond) Tam
Also a director
Chief Financial Officer and Director
|
Not stated | |
|
Qinghai Zhao
Chief Manufacturing Officer
|
Since 2020
6 years
|
|
|
Mickael Chane-Du
Chief Strategy Officer
|
Not stated | |
|
Yan Li
Senior Vice President, Bioinformatics and Information Technology
|
Since 2011
15 years
|
|
|
Xiaohong (Kristine) She
Senior Vice President, Head of Clinical Operations
|
Since 2011
15 years
|
|
|
Guizhong Liu
Senior Vice President of Early Drug Discovery
|
Since 2023
3 years
|
|
|
Songmao Zheng
Senior Vice President of Clinical Pharmacology and Quantitative Sciences
|
Not stated | |
|
Jiping Zha
Executive Vice President of Clinical Development
|
Since 2021
5 years
|
|
|
Alexander Goergen
Vice President, Head of Business Development
|
Since 2017
9 years
|
|
|
Wenlin Zeng
Vice President of Early Stage CMC
|
Since 2021
5 years
|
|
|
Chunfang (Vicky) Gu
Executive Director of Finance
|
Not stated | |
|
Ling (Jolin) Zhou
Executive Director of Human Resources
|
Since 2019
7 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. Adagene Inc. has not filed one with the SEC.
Loading...